All lobbying filings

Bluebird Strategies

Bluebird Strategies filed a Q2 report for Thermo Fisher Scientific Inc. on July 6, 2026, reporting $21,000 in lobbying income.

Lobbying for Thermo Fisher Scientific Inc. · Scientific product and technology company.

As filed: BLUEBIRD STRATEGIES for THERMO FISHER SCIENTIFIC INC.

All filings by Bluebird Strategies · Everything Thermo Fisher Scientific Inc. has reported

Filing · LD-2 quarterly report Q2 report

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jul 6, 2026

Income

$21,000

What the client paid this registrant for the period.

Client based in

Massachusetts

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Health Issues

Preeclampsia Risk Evaluation and Evidence-based Management through Personalized Testing Act PREEMPT Act (H.R. 9061) to promote the appropriate use of advanced preeclampsia biomarker testing as part of the Medicaid program. Seeking Senate companion legislation.

Bills named in this filing 1

H.R. 9061
PREEMPT Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.